Agios Pharmaceuticals
AGIO
238 hedge funds and large institutions have $1.67B invested in Agios Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 79 increasing their positions, 70 reducing their positions, and 44 closing their positions.
191% more call options, than puts
Call options by funds: $133M | Put options by funds: $45.6M
48% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 44
13% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 70
8% more funds holding
Funds holding: 221 → 238 (+17)
4.24% less ownership
Funds ownership: 109.29% → 105.05% (-4.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
35% less capital invested
Capital invested by funds: $2.55B → $1.67B (-$879M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$79.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$51.6M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$45.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$40.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$149M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$107M |
| 3 |
CC
Commodore Capital
New York
|
-$93.9M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$78.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$65.7M |
AGIO Hedge Fund Activity: Q4 2025 in Review
238 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2025, worth a combined $1.67B — down 35% from $2.55B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new AGIO positions and 44 closed out — a net gain of 21 holders — while 79 added to existing stakes and 70 trimmed.
The largest buyer was Armistice Capital, adding an estimated $79.7M. The largest seller was Bellevue Group, exiting entirely with an estimated $149M sold.
- 238 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2025, up from 221 in Q3 2025.
- Funds reported $1.67B of Agios Pharmaceuticals stock for Q4 2025, down 35% quarter-over-quarter.
- 65 funds opened new Agios Pharmaceuticals positions in Q4 2025 and 44 closed out, a net change of +21 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2025 was Armistice Capital, an estimated $79.7M added.
- The largest Agios Pharmaceuticals seller in Q4 2025 was Bellevue Group, an estimated $149M sold.
Based on aggregated 13F filings for Q4 2025.